Badie Banafsheh Moradmand, Soori Tahereh, Kheirandish Parastoo, Izadyar Saeed, SeyedAlinagh SeyedAhmad, Foroughi Maryam, Rostamian Alireza, Mohraz Minoo
Iranian Research Center for HIV/AIDS, Tehran University of Medical Sciences, Iran.
Acta Med Iran. 2011;49(7):460-7.
Bone disorders have emerged as a worrisome complication in HIV-infected patients in recent years. It is not clear that HIV infection itself or antiretroviral treatment or both are causes of bone loss. However, most studies have found a high prevalence of osteopenia and osteoporosis in HIV/AIDS patients. The objectives of this study were to determine the prevalence of osteopenia and osteoporosis in HIV-infected patients either untreated or receiving Highly Active Antiretroviral Therapy as compared with HIV negative persons. We also assessed the factors associated with these conditions. Bone Mineral Density was assessed by Dual Energy X-Ray Absorptiometry scans at the hip and lumbar spine in 36 AIDS patients receiving antiretroviral therapy and 44 HIV infected patients not receiving antiretroviral therapy (naïve patients) and 40 HIV negative individuals as control. Factors that affect BMD were also determined. Prevalence of osteopenia or osteoporosis in different regions was significantly higher in HIV/AIDS patients compared with HIV negative subjects (77.3% in HIV positive naïve patients, 86.1% in HAART-treated patients and 60% in the control group, P=0.002). Mean serum alkaline phosphatase was higher in HIV/AIDS patients than the control group (P=0.003). Osteopenia and osteoporosis in HIV-infected patients were associated with duration of HIV infection (P<0.0001) and antiretroviral treatment (P=0.012). Prevalence of osteopenia and osteoporosis in HIV/AIDS patients was higher than HIV negative individuals. Osteopenia and osteoporosis in HIV/AIDS patients was associated with duration of HIV infection and antiretroviral treatment.
近年来，骨骼疾病已成为HIV感染患者中令人担忧的并发症。目前尚不清楚HIV感染本身、抗逆转录病毒治疗或两者是否为骨质流失的原因。然而，大多数研究发现HIV/AIDS患者中骨量减少和骨质疏松的患病率很高。本研究的目的是确定未接受治疗或接受高效抗逆转录病毒治疗的HIV感染患者与HIV阴性者相比，骨量减少和骨质疏松的患病率。我们还评估了与这些情况相关的因素。通过双能X线吸收法扫描对36例接受抗逆转录病毒治疗的艾滋病患者、44例未接受抗逆转录病毒治疗的HIV感染患者（初治患者）和40例HIV阴性个体作为对照进行髋部和腰椎骨密度评估。还确定了影响骨密度的因素。与HIV阴性受试者相比，HIV/AIDS患者不同区域骨量减少或骨质疏松的患病率显著更高（HIV阳性初治患者中为77.3%，接受高效抗逆转录病毒治疗患者中为86.1%，对照组中为60%，P=0.002）。HIV/AIDS患者的平均血清碱性磷酸酶高于对照组（P=0.003）。HIV感染患者的骨量减少和骨质疏松与HIV感染持续时间（P<0.0001）和抗逆转录病毒治疗（P=0.012）有关。HIV/AIDS患者中骨量减少和骨质疏松的患病率高于HIV阴性个体。HIV/AIDS患者的骨量减少和骨质疏松与HIV感染持续时间和抗逆转录病毒治疗有关。
